Anika Therapeutics, Inc. (ANIK) Cash Flow Statement
Anika Therapeutics, Inc. (ANIK) generated $6.0M of operating cash flow over the twelve months to 2026-06-30, spent $5.4M on capital expenditure and had free cash flow of $562000, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANIKAnika Therapeutics, Inc.Follow ANIK — free
—
Price chart with a free account
- Market cap
- 286.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 10.2 | 10.5 | 25.2 | 40.0 | 39.9 | 24.4 | 40.8 | 34.9 | 37.0 | 13.1 | 8.4 | 4.4 | -1.8 | 5.4 | 11.2 | 6.0 | |
| Capital expenditure | 1.4 | 1.5 | 0.4 | 1.6 | 9.2 | 14.0 | 9.0 | 4.7 | 2.8 | 1.6 | 5.1 | 7.5 | 5.4 | 7.7 | 6.8 | -5.4 | |
| Free cash flow | 8.8 | 9.0 | 24.7 | 38.4 | 30.7 | 10.4 | 31.8 | 30.3 | 34.2 | 11.4 | 3.3 | -3.1 | -7.2 | -2.3 | 4.4 | 0.6 | |
| Share repurchases | — | — | — | — | — | 25.0 | — | 30.0 | 30.0 | 0.0 | 0.0 | 0.0 | 5.0 | 10.9 | 9.5 | — | |
| Stock-based compensation | 1.2 | 1.2 | 1.3 | 1.6 | 2.2 | 3.4 | 5.8 | 11.0 | 6.1 | 5.4 | 11.1 | 14.3 | 15.2 | 13.1 | 10.1 | — |
USD millions · SEC XBRL
Anika Therapeutics, Inc. — questions
- What is Anika Therapeutics, Inc.'s operating cash flow?
- $6.0M over the twelve months to 2026-06-30.
- How much does Anika Therapeutics, Inc. spend on capital expenditure?
- $5.4M over the twelve months to 2026-06-30.
- What is Anika Therapeutics, Inc.'s free cash flow?
- $562000 over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Anika Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.